Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Early and effective treatment of KCNQ 2 encephalopathy

Open access
Pisano, Tiziana, Numis, Adam L., Heavin, Sinéad B., Weckhuysen, Sarah, Angriman, Marco, Suls, Arvid, Podesta, Barbara, Thibert, Ronald L., Shapiro, Kevin A., Guerrini, Renzo, Scheffer, Ingrid E., Marini, Carla, Cilio, Maria Roberta·2015·Epilepsia

Abstract

Summary: Objectives: To describe the antiepileptic drug ( AED ) treatment of patients with early infantile epileptic encephalopathy due to KCNQ 2 mutations during the neonatal phase and the first year of life. Methods: We identified 15 patients and reviewed the electroclinical, neuroimaging, and AED treatment data. Results: Seizure onset was between 1 and 4 days of age with daily tonic asymmetric, focal and clonic seizures in nine patients and status epilepticus in the remaining six. Electroencephalography ( EEG ) showed multifocal epileptiform abnormalities in nine patients and a burst‐suppression pattern in six. All patients were trialed with adequate daily doses of several AED s before they reached seizure freedom. Six patients (40%) achieved seizure control within 2 weeks of carbamazepine ( CBZ ) administration and five (33%) were seizure‐free with phenytoin ( PHT ). The last four patients (27%) were successfully treated with topiramate ( TPM ) (two patients), levetiracetam ( LEV ) (one), and a combination of LEV with TPM (one). Most patients reached seizure freedom within the first year of life and remained seizure‐free thereafter. Twelve patients had moderate‐to‐severe developmental delay at follow‐up. However, the two patients whose seizures ceased within a few days of onset showed only mild cognitive impairment. Significance: Our findings suggest that drugs acting on sodium channels including CBZ and PHT should be considered as first‐line treatment in patients with KCNQ 2 encephalopathy. Voltage‐gated sodium and potassium channels co‐localize at the neuronal membrane. Therefore, the efficacy of drugs acting as sodium‐channel blockers could be linked to their modulating effect on both channels. The type of KCNQ 2 mutation might influence AED response as well as developmental outcome. Early recognition of KCNQ 2 encephalopathy followed by the most appropriate and effective treatment may be important for reducing the neurodevelopmental impairment associated with this disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.12984

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 301

Metadata

Authors
Pisano, T., Numis, A. L., Heavin, S. B., Weckhuysen, S., Angriman, M., Suls, A., Podesta, B., Thibert, R. L., Shapiro, K. A., Guerrini, R., Scheffer, I. E., Marini, C., & Cilio, M. R.
Venue
Epilepsia
Publisher
Wiley
Published
2015-04-16
Volume
56
Issue
5
Pages
685-691
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2034163951
Cited by
301
References
24
FWCI
15.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early and effective treatment of KCNQ 2 encephalopathy. https://app.cochat.ai/papers/10.1111/epi.12984
The paper
Pisano, T., Numis, A. L., Heavin, S. B., Weckhuysen, S., Angriman, M., Suls, A., Podesta, B., Thibert, R. L., Shapiro, K. A., Guerrini, R., Scheffer, I. E., Marini, C., & Cilio, M. R. (2015). Early and effective treatment of KCNQ 2 encephalopathy. Epilepsia. https://doi.org/10.1111/epi.12984

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.